Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy

摘要: Reactivation of hepatitis B virus (HBV) is a known complication that occurs in patients receiving chemotherapy especially for malignant lymphoma. The increased risk lymphoma parallels the potency immunosuppressive treatment regimens are provided. B-cell-depleting therapy such as anti-CD20 monoclonal antibodies, when combined with conventional chemotherapy, significantly increases HBV reactivation, even resolved infection. first reports reactivation emerged only 4 years after its US Food and Drug Administration approval. Today, these drugs carry alert warnings on hepatic dysfunction Many other new/novel agents active against have since then, targeting different pathways involved pathogenesis, including histone deacetylase inhibitors, antibody-drug conjugates, proteasome inhibitors. These various differing depths mechanisms immunosuppression, necessitating due diligence administrating compounds to prevent infective complications which can lead liver failure death. This review focuses non-Hodgkin treatment, particular approved novel agents. We also discuss current recommendations screening role prophylactic antiviral during treatment.